|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Hydrolase
|
 |
|
Title:
|
 |
Prommp-2/timp-2 complex
|
|
Structure:
|
 |
72 kda type iv collagenase. Chain: a, b. Synonym: gelatinase a, 72 kda gelatinase, matrix metalloproteinase-2, mmp-2, tbe-1. Engineered: yes. Mutation: yes. Metalloproteinase inhibitor 2. Chain: c, d. Synonym: tissue inhibitor of metalloproteinases-2, timp-2.
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Expressed in: trichoplusia ni. Expression_system_taxid: 7111. Expression_system_cell_line: h5.
|
|
Biol. unit:
|
 |
Hetero-Dimer (from PDB file)
|
|
Resolution:
|
 |
|
3.10Å
|
R-factor:
|
0.278
|
R-free:
|
0.333
|
|
|
Authors:
|
 |
E.Morgunova,A.Tuuttila,U.Bergmann,K.Tryggvason
|
Key ref:
|
 |
E.Morgunova
et al.
(2002).
Structural insight into the complex formation of latent matrix metalloproteinase 2 with tissue inhibitor of metalloproteinase 2.
Proc Natl Acad Sci U S A,
99,
7414-7419.
PubMed id:
DOI:
|
 |
|
Date:
|
 |
|
02-Apr-02
|
Release date:
|
09-Jul-02
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
Chains A, B:
E.C.3.4.24.24
- gelatinase A.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Cleavage of gelatin type I and collagen types IV, V, VII, X. Cleaves the collagen-like sequence Pro-Gln-Gly-|-Ile-Ala-Gly-Gln.
|
 |
 |
 |
 |
 |
Cofactor:
|
 |
Ca(2+); Zn(2+)
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
Proc Natl Acad Sci U S A
99:7414-7419
(2002)
|
|
PubMed id:
|
|
|
|
|
| |
|
Structural insight into the complex formation of latent matrix metalloproteinase 2 with tissue inhibitor of metalloproteinase 2.
|
|
E.Morgunova,
A.Tuuttila,
U.Bergmann,
K.Tryggvason.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Matrix metalloproteinases (MMPs) are a family of multidomain enzymes involved in
the physiological degradation of connective tissue, as well as in pathological
states such as tumor invasion and arthritis. Apart from transcriptional
regulation, MMPs are controlled by proenzyme activation and a class of specific
tissue inhibitors of metalloproteinases (TIMPs) that bind to the catalytic site.
TIMP-2 is a potent inhibitor of MMPs, but it has also been implicated in a
unique cell surface activation mechanism of latent MMP-2/gelatinase A/type IV
collagenase (proMMP-2), through its binding to the hemopexin domain of proMMP-2
on the one hand and to a membrane-type MMP activator on the other. The present
crystal structure of the human proMMP-2/TIMP-2 complex reveals an interaction
between the hemopexin domain of proMMP-2 and the C-terminal domain of TIMP-2,
leaving the catalytic site of MMP-2 and the inhibitory site of TIMP-2 distant
and spatially isolated. The interfacial contact of these two proteins is
characterized by two distinct binding regions composed of alternating
hydrophobic and hydrophilic interactions. This unique structure provides
information for how specificity for noninhibitory MMP/TIMP complex formation is
achieved.
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 1.
Fig. 1. Structure of the proMMP-2/TIMP-2 complex. Overall
conformation: the proteinase and inhibitor interact via their
C-terminal domains. The catalytic site of MMP-2 and the
inhibitory active site of TIMP-2 are turned away from each
other. This topology excludes an inhibitory interaction between
the proteinase and inhibitor and implies that both proteins
remain fully functional in the complex. Catalytic and structural
Zn2+ ions are colored red and Ca^2+ ion purple. The -propeller
blades of the hemopexin domain are numbered from I to IV. Two
light blue ellipsoids in blades III and IV indicate two areas of
interaction between proMMP-2 and TIMP-2 molecules.
|
 |
Figure 4.
Fig. 4. Stereo ribbon diagram of the hypothetical model
of complex formed between proMMP-2, TIMP-2, and the catalytic
domain of MT1-MMP. In the model shown, TIMP-2 is a hybrid with
its C-terminal domain taken from the presented proMMP-2/TIMP-2
complex structure (magenta) and the N-terminal TIMP-2 half (red)
is obtained from the model of the MT1-MMP/TIMP-2 inhibitory
complex (Protein Data Bank code 1BUV) (26). Such combining was
done because of the structural differences between complexed and
uncomplexed forms of TIMP-2 molecules. Coloring for proMMP-2:
the propeptide is pink, catalytic domain is blue, three
fibronectin-like domains are green, and the hemopexin domain is
yellow; for MT1-MMP: the catalytic domain is light blue.
|
 |
|
|
| |
Figures were
selected
by an automated process.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
L.Shen,
Z.Liu,
Y.Tu,
L.Xu,
X.Sun,
and
S.Wu
(2011).
Regulation of MMP-2 expression and activity by β-1,3-N-acetylglucosaminyltransferase-8 in AGS gastric cancer cells.
|
| |
Mol Biol Rep,
38,
1541-1550.
|
 |
|
|
|
|
 |
E.S.Radisky,
and
D.C.Radisky
(2010).
Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer.
|
| |
J Mammary Gland Biol Neoplasia,
15,
201-212.
|
 |
|
|
|
|
 |
J.Ciriza,
and
M.E.García-Ojeda
(2010).
Expression of migration-related genes is progressively upregulated in murine Lineage-Sca-1+c-Kit+ population from the fetal to adult stages of development.
|
| |
Stem Cell Res Ther,
1,
14.
|
 |
|
|
|
|
 |
K.Brew,
and
H.Nagase
(2010).
The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity.
|
| |
Biochim Biophys Acta,
1803,
55-71.
|
 |
|
|
|
|
 |
A.C.Nicolescu,
A.Holt,
A.D.Kandasamy,
P.Pacher,
and
R.Schulz
(2009).
Inhibition of matrix metalloproteinase-2 by PARP inhibitors.
|
| |
Biochem Biophys Res Commun,
387,
646-650.
|
 |
|
|
|
|
 |
L.Troeberg,
K.Fushimi,
S.D.Scilabra,
H.Nakamura,
V.Dive,
I.B.Thøgersen,
J.J.Enghild,
and
H.Nagase
(2009).
The C-terminal domains of ADAMTS-4 and ADAMTS-5 promote association with N-TIMP-3.
|
| |
Matrix Biol,
28,
463-469.
|
 |
|
|
|
|
 |
X.Zhang,
Y.H.Shen,
and
S.A.LeMaire
(2009).
Thoracic aortic dissection: are matrix metalloproteinases involved?
|
| |
Vascular,
17,
147-157.
|
 |
|
|
|
|
 |
G.Murphy,
and
H.Nagase
(2008).
Progress in matrix metalloproteinase research.
|
| |
Mol Aspects Med,
29,
290-308.
|
 |
|
|
|
|
 |
J.Melendez-Zajgla,
L.Del Pozo,
G.Ceballos,
and
V.Maldonado
(2008).
Tissue inhibitor of metalloproteinases-4. The road less traveled.
|
| |
Mol Cancer,
7,
85.
|
 |
|
|
|
|
 |
N.Díaz,
and
D.Suárez
(2008).
Molecular dynamics simulations of the active matrix metalloproteinase-2: positioning of the N-terminal fragment and binding of a small peptide substrate.
|
| |
Proteins,
72,
50-61.
|
 |
|
|
|
|
 |
A.L.Newsome,
J.P.Johnson,
R.L.Seipelt,
and
M.W.Thompson
(2007).
Apolactoferrin inhibits the catalytic domain of matrix metalloproteinase-2 by zinc chelation.
|
| |
Biochem Cell Biol,
85,
563-572.
|
 |
|
|
|
|
 |
F.E.Jacobsen,
J.A.Lewis,
and
S.M.Cohen
(2007).
The Design of Inhibitors for Medicinally Relevant Metalloproteins.
|
| |
ChemMedChem,
2,
152-171.
|
 |
|
|
|
|
 |
L.Pérez,
J.E.Kerrigan,
X.Li,
and
H.Fan
(2007).
Substitution of methionine 435 with leucine, isoleucine, and serine in tumor necrosis factor alpha converting enzyme inactivates ectodomain shedding activity.
|
| |
Biochem Cell Biol,
85,
141-149.
|
 |
|
|
|
|
 |
M.Roderfeld,
J.Graf,
B.Giese,
R.Salguero-Palacios,
A.Tschuschner,
G.Müller-Newen,
and
E.Roeb
(2007).
Latent MMP-9 is bound to TIMP-1 before secretion.
|
| |
Biol Chem,
388,
1227-1234.
|
 |
|
|
|
|
 |
Y.B.Hu,
D.G.Li,
and
H.M.Lu
(2007).
Modified synthetic siRNA targeting tissue inhibitor of metalloproteinase-2 inhibits hepatic fibrogenesis in rats.
|
| |
J Gene Med,
9,
217-229.
|
 |
|
|
|
|
 |
Y.Sakakura,
Y.Hosokawa,
E.Tsuruga,
K.Irie,
M.Nakamura,
and
T.Yajima
(2007).
Contributions of matrix metalloproteinases toward Meckel's cartilage resorption in mice: immunohistochemical studies, including comparisons with developing endochondral bones.
|
| |
Cell Tissue Res,
328,
137-151.
|
 |
|
|
|
|
 |
A.G.Remacle,
D.V.Rozanov,
M.Fugere,
R.Day,
and
A.Y.Strongin
(2006).
Furin regulates the intracellular activation and the uptake rate of cell surface-associated MT1-MMP.
|
| |
Oncogene,
25,
5648-5655.
|
 |
|
|
|
|
 |
M.B.Larsen,
R.W.Stephens,
N.Brünner,
H.J.Nielsen,
L.H.Engelholm,
I.J.Christensen,
W.G.Stetler-Stevenson,
and
G.Høyer-Hansen
(2005).
Quantification of tissue inhibitor of metalloproteinases 2 in plasma from healthy donors and cancer patients.
|
| |
Scand J Immunol,
61,
449-460.
|
 |
|
|
|
|
 |
M.Björklund,
and
E.Koivunen
(2005).
Gelatinase-mediated migration and invasion of cancer cells.
|
| |
Biochim Biophys Acta,
1755,
37-69.
|
 |
|
|
|
|
 |
M.Wang,
D.Yoshida,
S.Liu,
and
A.Teramoto
(2005).
Inhibition of cell invasion by indomethacin on glioma cell lines: in vitro study.
|
| |
J Neurooncol,
72,
1-9.
|
 |
|
|
|
|
 |
N.Nour,
G.Mayer,
J.S.Mort,
A.Salvas,
M.Mbikay,
C.J.Morrison,
C.M.Overall,
and
N.G.Seidah
(2005).
The cysteine-rich domain of the secreted proprotein convertases PC5A and PACE4 functions as a cell surface anchor and interacts with tissue inhibitors of metalloproteinases.
|
| |
Mol Biol Cell,
16,
5215-5226.
|
 |
|
|
|
|
 |
G.Klein,
E.Vellenga,
M.W.Fraaije,
W.A.Kamps,
and
E.S.de Bont
(2004).
The possible role of matrix metalloproteinase (MMP)-2 and MMP-9 in cancer, e.g. acute leukemia.
|
| |
Crit Rev Oncol Hematol,
50,
87.
|
 |
|
|
|
|
 |
K.Shimizu,
and
N.Oku
(2004).
Cancer anti-angiogenic therapy.
|
| |
Biol Pharm Bull,
27,
599-605.
|
 |
|
|
|
|
 |
P.Osenkowski,
M.Toth,
and
R.Fridman
(2004).
Processing, shedding, and endocytosis of membrane type 1-matrix metalloproteinase (MT1-MMP).
|
| |
J Cell Physiol,
200,
2.
|
 |
|
|
|
|
 |
W.Bode,
and
K.Maskos
(2003).
Structural basis of the matrix metalloproteinases and their physiological inhibitors, the tissue inhibitors of metalloproteinases.
|
| |
Biol Chem,
384,
863-872.
|
 |
|
|
|
|
 |
X.S.Puente,
L.M.Sánchez,
C.M.Overall,
and
C.López-Otín
(2003).
Human and mouse proteases: a comparative genomic approach.
|
| |
Nat Rev Genet,
4,
544-558.
|
 |
|
|
|
|
 |
C.M.Overall,
and
C.López-Otín
(2002).
Strategies for MMP inhibition in cancer: innovations for the post-trial era.
|
| |
Nat Rev Cancer,
2,
657-672.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
|
');
}
}
 |